参考文献/References:
[1] 陈 竺. 全国第三次死因回顾抽样调查报告[M]. 北京：中
国协和医科大学出版社，2008. 14-17.
[2] 2014中国脑卒中大会[J]. 中国医学前沿杂志（电子版），
2014，（4）：114-114.
[3] Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/
unstable plaque ［J]. Arterioscler Thromb Vasc Biol, 2010,
30(7): 1282-1292.
[4] Wvan Lammeren G, L Moll F, Borst GJ, et al. Atherosclerotic
plaque biomarkers: beyond the horizon of the vulnerable
plaque [J]. Current Cardiology Review, 2011, 7: 22-27.
[5] Ross R. Atherosclerosis--an inflammatory disease [J]. N
Engl J Med, 1999, 340(2): 15-126.
[6] Ammirati E, Moroni F, Norata GD, et al. Markers of inflam-
mation associated with plaque progression and instability in
patients with carotid atherosclerosis [J]. Mediators Inflamm,
2015, 2015: 718329
[7] Naghavi M，Libby P, Falk E, et al. From vulnerable plaque
to vulnerable patient: a call for new definitions and risk
assessment strategies: PartⅠ[J]. Circulation, 2003, 108(14):
1664-1672.
[8] Finn AV, Nakano M, Narula J, et al. Concept of vulnerable/
unstable plaque [J]. Arterioscler Thromb Vasc Biol, 2010,
30(7): 1282-1292.
[9] Shah PK. Inflammation and plaque vulnerability [J]. Cardio-
vasc Drugs Ther, 2009, 23: 31-40.
[10] Libby P. Molecular and cellular mechanisms of the throm-
botic complications of atherosclerosis [J]. J Lipid Res, 2009,
50(Suppl): S352-357.
[11] Virmani R, Kolodgie FD, Burke AP, et al. Atherosclerotic
plaque progression and vulnerability to rupture: angiogene-
sis as a source of intraplaque hemorrhage[J]. Arterioscler
Thromb Vasc Biol, 2005, 25(10): 2054-2061.
[12] Chang X, Feng J, Ruan L, et al. Positive correlation between
neovascularization degree of carotid atherosclerosis deter-
mined by contrast-enhanced ultrasound and level of serum
C-reactive protein [J].Vasa, 2015, 44(3): 187-194.
[13] Chenq C, Chrifi I, Pasterkamp G, et al. Biological mecha-
nisms of microvessel formation in advanced atherosclerosis:
the big five [J]. Trends Cardiovasc Med, 2013, 23(5): 153-
164.
[14] Baldassarre D, De Jong A, Amato M, et al. Carotid intima-
media thickness and markers of inflammation, endothelial
damage and hemostasis [J]. Ann Med, 2008, 40(1): 21-44.
[15] Ridker PM, Danielson E, Fonseca FA, et al. Reduction in
C-reactive protein and LDL cholesterol and cardiovascular
event rates after initiation of rosuvastatin: a prospective
study of the JUPITER trial [J]. Lancet, 2009, 373(9670):
1175-1182.
[16] Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to
prevent vascular events in men and women with elevated
C-reactive protein [J]. N Engl J Med, 2008, 359(21): 2195-
2207.
[17] Hansson GK, Hermansson A. The immune system in athero-
sclerosis [J]. Nat Immunol, 2011, 12: 204-212.
[18] Patterson CC, Smith AE, Yarnell JW, et al. The associations
of interleukin-6 (IL-6) and downstream inflammatory
markers with risk of cardiovascular disease:the caerphilly
study [J]. Atherosclerosis, 2010, 209: 551-557.
[19] Yuan M, Fu H, Ren L, et al. Soluble CD40 ligand promotes
macrophage foam cell formation in the etiology of atherosc-
lerosis [J]. Cardiology, 2015, 131(1): 1-12.
[20] Wanq C, Yan J, Yanq P, et al. The relationship between
CD40 gene polymorphism and unstable coronary atherosc-
lerotic plaques [J]. Clin Cardiol, 2010, 33(6): E55-60.
[21] 张 白，惠品晶，国 风，等. CD40及基质金属蛋白酶在
颈动脉内膜剥脱术斑块中的表达及影响斑块稳定性的
研究[J]. 中华神经外科杂志，2015，31（1）：84-87.
[22] Gostiljac D, Dordevid PB, Djurid D, et al. The importance
of defining serum MMP-9 concentration in diabetics as an
early marker of the rupture of atheromatous plaque in acute
coronary syndrome [J]. Acta Physiol Hung, 2011, 98(1): 91-
97.
[23] Wagsater D, Zhu C, Bjorkegren J, et al. MMP-2 and MMP-9
are prominent matrix metalloproteinases during atheroscle-
rosis development in the Ldlr(-/-)Apob(100/100) mouse [J].
Int J MoI Med, 2011, 28(2): 247-253．
[24] Lee YH, Kim TY, Hong YM. Metalloproteinase-3 genoty-
peas a predictor of cardiovascular risk in hypertensive
adolescent [J]. Korean Circ J, 2009, 39(8): 328-334.
[25] Masseau I, Bowles DK. Carotid endothelial VCAM-1 is an
early marker of carotid atherosclerosis and predicts coronary
artery disease in swine [J]. J Biomed Sci Eng, 2015, 8(11):
789-796.
[26] De Caterina R, Basta G, Lazzerini G, et al. Soluble vascular
cell adhesion molecule-1 as a biohumoral correlate of athe-
rosclerosis [J]. Arterioscler Thromb Vasc Biol, 1997, 17
(11): 2646-2654.
[27] Park JG, Ryu SY, Junq IH, et al. Evaluation of VCAM-1
antibodies as therapeutic agent for atherosclerosis in apoli-
poprotein E-deficient mice [J]. Atherosclerosis, 2013, 226
(2): 356-363.
[28] Noonan T, Lukas S, Peet GW, et al. The oxidase activity of
vascular adhesion protein-1(VAP-1)is essential for function
[J]. Am J Clin Exp Immunol, 2013, 2(2): 172-185.
[29] 陈大伟，王 涛，郭广进，等. 人颈动脉斑块血管粘附蛋白
1的表达及其与炎症的关系[J].中华保健医学杂志，
2014，16（3）：187-189.
[30] Fang R, Zhang N, Wang C, et al. Relations between plasma
ox-LDL and carotid plaque among Chinese Han ethnic
group [J]. Neurol Res, 2011, 33(5): 460-466.